| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -26.6 | -17.0 |
| Net income | -27.3 | -17.1 |
| EPS (diluted, $ a share) | $-0.58 | $-18.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: COAG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Hemab Therapeutics Holdings, Inc.: key numbers
- Share price
- $39.06Close, Nov 17
- Market cap
- $1.83B
- Shares outstanding
- 46.73MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Hemab Therapeutics Holdings, Inc.
All →Hemab Therapeutics Holdings Financial Results
Hemab Therapeutics reported financial results for the third quarter of 2026 and provided a corporate update on its clinical pipeline. The company transitioned to a late-stage biotech by initiating the SOLARA Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia and dosing the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding.
- Term
- Q3 2026
“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”
Benny Sørensen, MD, PhD, CEO of Hemab
“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”
Benny Sørensen, MD, PhD, CEO of Hemab
Hemab Therapeutics Holdings Executive Compensation
Hemab Therapeutics Holdings, Inc. has appointed Keli Walbert to its Board of Directors and Audit Committee, effective September 24, 2026. Ms. Walbert will receive an annual cash retainer of $40,000 for board service plus $10,000 for committee service, along with an initial grant of options to purchase 36,000 shares of common stock vesting over three years. This appointment fills a Class I director seat with a term expiring at the 2027 annual meeting.
- Counterparty
- Keli Walbert